Literature DB >> 31261403

Fracture Risk After Initiation of Use of Canagliflozin.

Michael Fralick1, Seoyoung C Kim1, Sebastian Schneeweiss1, Dae Kim1, Donald A Redelmeier2, Elisabetta Patorno1.   

Abstract

Entities:  

Year:  2019        PMID： 31261403     DOI： 10.7326/L19-0320

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  2 in total

1.  Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.

Authors:  Elisabetta Patorno; Ajinkya Pawar; Deborah J Wexler; Robert J Glynn; Lily G Bessette; Julie M Paik; Mehdi Najafzadeh; Kimberly G Brodovicz; Anouk Déruaz-Luyet; Sebastian Schneeweiss
Journal:  Diabetes Obes Metab       Date:  2021-12-01       Impact factor: 6.577

Review 2.  Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy.

Authors:  Mouhamed Nashawi; Mahmoud S Ahmed; Toka Amin; Mujahed Abualfoul; Robert Chilton
Journal:  World J Cardiol       Date:  2021-12-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.